On April 21, 2026, Tortugas Neuroscience announced its launch, signaling a new player in the pharmaceutical industry focused on brain disorders and other medical conditions.
The company plans to develop drugs that are licensed from two notable partners: the Chinese drugmaker Jiangsu Hansoh and the Japanese pharmaceutical firm Eisai.
This initiative reflects a growing interest in addressing complex neurological issues through innovative drug development strategies.